不同来源胱氨酸片肝脏保护生物活性比较研究

Study on bioactivity of cystine tablets of different sources in liver protection

目的:比较3批不同来源胱氨酸片(受试样品Ⅰ、Ⅱ、Ⅲ)在肝脏保护作用方面的差异,为该品种的再评价和标准提高提供试验依据。方法:采用酒精肝损伤模型,灌胃给予大鼠人体推荐剂量30倍的来源不同的胱氨酸片21 d后,采用试剂盒检测动物肝匀浆中丙二醛(MDA)含量及超氧化物歧化酶(SOD)活力,同时检测动物血清中总胆红素(TBIL)、丙氨酸转氨酶(ALT)、谷草转氨酶(AST)等生化指标。结果:受试样品Ⅲ可明显降低模型大鼠MDA含量,并增加SOD的活力,受试样品Ⅰ与受试样品Ⅱ对MDA和SOD无明显影响。各受试样品均可明显抑制由酒精引起的TBIL升高,但在同一模型条件下对ALT和AST无明显影响。结论:3批不同来源的胱氨酸片都是含量测定合格的受试样品,但在肝脏保护生物活性方面确表现出了差异。原料药胱氨酸来源不同,胱氨酸片生产工艺存在差别,药品效期不同,均可能会对胱氨酸片的降总胆红素、抗氧化作用等肝脏保护生物活性产生影响。

Objective: To compare the differences in the protective effect of three different sources of cystine tablets in the liver,and to provide relevant evidence for the reappraisal and standard improvement of the cultivars. Methods: Using alcoholic liver injury model,rats were given gavage 30 times of the recommended dose of human body with the same specifications of Cystine Tablets for 21 days. Propylaminotransferase( ALT),aspartate aminotransferase( AST),total bilirubin( TBIL) were measured in animal serum and the content of malondialdehyde( MDA) and superoxide dismutase( SOD) in the liver homogenate were measured by special detection kit. Results: Cystine tablets from different origins could significantly inhibit the increase of TBIL caused by alcohol,but had no significant effect on ALT and AST under the same model. The tested sample Ⅲ could significantly decrease the MDA content of the model rats and increase the activity of SOD,while the other two batches did not detect such effects. Conclusion: The cystic acid tablets of different origins showed hepatocyte protective effect,but the effect on MDA and SOD was different. The above three groups of different sources of cystine tablets in the physical and chemical testing content are in line with the provisions,consider these differences may be related to the different source of raw materials and production processes.